Immediate Impact
6 from Science/Nature 68 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Works of Adam Bryant being referenced
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
2023
miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death
2012
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Adam Bryant | 176 | 199 | 25 | 155 | 28 | 484 | |
| Sangeetha Venugopal | 321 | 238 | 52 | 58 | 40 | 547 | |
| Mikael Åberg | 111 | 171 | 2 | 98 | 38 | 552 | |
| Maciej Kaźmierczak | 180 | 158 | 20 | 50 | 40 | 448 | |
| Konstantin Schlick | 110 | 104 | 28 | 70 | 34 | 507 | |
| Michael F. Guerrera | 186 | 167 | 11 | 26 | 29 | 508 | |
| M. Bauer | 62 | 259 | 19 | 105 | 29 | 565 | |
| Tobias Silzle | 94 | 160 | 4 | 76 | 20 | 415 | |
| Anne M. Sproul | 322 | 101 | 42 | 53 | 20 | 523 | |
| Morgan L. McLemore | 219 | 109 | 42 | 33 | 37 | 566 | |
| Clifton C. Mo | 230 | 206 | 41 | 31 | 44 | 463 |
All Works
Login with ORCID to disown or claim papers
Loading papers...